About Basilea Pharmaceutica AG

Company Description

Basilea is a revenue-generating, commercial-stage Swiss biopharmaceutical company. Our activities are focused in the areas of hospital antibiotics, hospital antifungals and cancer treatments. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and three oncology drug candidates in clinical development. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 and is located in the life sciences hub of the Basel area. Basilea has about 150 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.

Year founded

2000

Served area

Worldwide

Headcount

150

Headquarters

Grenzacherstrasse 487, 4058 Basel – Switzerland

Shareholder information

Shares outstanding

12,992,166

IPO

March 24, 2004

Stock exchange(s)

SIX Swiss Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.